rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TEVA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Teva’s R&D chief Eric Hughes to depart pharmaceutical company
      5h agoInvesting.comTEVA
      Glenview ups stakes in Meta, Teva; cuts CVS, Block in Q3; exits DKS, STM (META:NASDAQ)
      Nov 17Seeking AlphaCVSTEVA
      FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder
      Nov 16BenzingaTEVA
      Teva settles US price-fixing case over generic drugs
      Nov 16Investing.comTEVA
      Teva settles US states’ drug price-fixing case By Reuters
      Nov 16Investing.comTEVA
      US FDA approves at-home use of BioXcel's agitation drug
      Nov 16ReutersBTAITEVA
      Teva Pharmaceutical Industries Limited (TEVA) R&D Day: Pivot to Growth Strategy, Pipeline and Financial Outlook - Slideshow

      2026-11-13. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with this event.

      Nov 13Seeking AlphaTEVA
      Piper Sandler raises Teva stock price target on pipeline strength
      Nov 12Investing.comTEVA
      Teva stock hits 52-week high at 43.5 USD
      Nov 12Investing.comTEVA
      Jefferies reiterates Teva Pharma stock rating citing pipeline progress
      Nov 12Investing.comTEVA
      H.C. Wainwright reiterates Teva Pharma stock rating on pipeline outlook
      Nov 12Investing.comTEVA
      Teva Pharmaceutical Industries (TEVA) Holds First R&D Day With New Pipeline Milestones
      Nov 12Yahoo FinanceTEVA
      Teva Pharmaceutical Industries (TEVA) Earnings Put Its Turnaround Valuation Back In Focus
      Nov 12Yahoo FinanceTEVA
      Teva CEO Richard Francis goes one-on-one with Jim Cramer

      Teva President and CEO Richard Francis joins 'Mad Money' host Jim Cramer to talk its first R&D day, where it is seeing growth opportunities, its individual offerings, and more.

      Nov 12CNBCTEVA
      Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030
      Nov 11Yahoo FinanceTEVA
      Teva Outlines Aggressive R&D Strategy with $7 Billion in Innovative Medicine Revenue by 2030
      Nov 11BenzingaTEVA
      Teva targets $6-7 billion in innovative medicines revenue by 2030
      Nov 11Investing.comTEVA
      Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
      Nov 11Yahoo FinanceTEVA
      FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week
      Nov 9Yahoo FinanceCYTKSMMTTEVA
      Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights: Innovative ...

      Teva Pharmaceutical Industries Ltd (TEVA) lifted full-year revenue and free cash flow guidance on the strength of AUSTEDO, AJOVY, and UZEDY, even as total revenue slipped 2% and generics fell 16%.

      Nov 6Yahoo FinanceTEVA
      Teva Pharmaceutical Industries Limited’s (TEVA) Innovative Brands Drive Stronger Growth
      Nov 5Yahoo FinanceTEVA
      Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
      Nov 4Yahoo FinanceTEVA
      MindWalk secures multi-year AI deal with Teva Australia
      Nov 4Investing.comTEVA
      MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows
      Nov 4Yahoo FinanceTEVA
      H.C. Wainwright raises Teva Pharma stock price target to $54
      Nov 4Investing.comTEVA
      What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
      Nov 4Yahoo FinanceTEVA
      BofA raises Teva Pharma stock price target on strong quarter
      Nov 4Investing.comTEVA
      How Investors Are Reacting To Teva Pharmaceutical Industries (TEVA) Earnings Beat

      Teva Pharmaceutical Industries reported Q3 2026 sales of US$4.4b with earnings that topped some analyst expectations, while branded drugs AUSTEDO, AJOVY, UZEDY and new schizophrenia therapy WELTRUZA together produced strong revenue momentum and led management to raise the 2026 outlook for these key products. The new U.S. biosimilars agreement with Samsung Bioepis on infliximab-abda and etanercept-ykro adds another revenue pillar alongside Teva's higher margin central nervous system...

      Nov 3Yahoo FinanceTEVA
      Why Is Teva (TEVA) Dropping A Drug Trial While Raising Its Outlook?

      Teva Pharmaceutical Industries (NYSE:TEVA) ended its Phase 2 TOPAS-MSA trial of emrusolmin after an interim futility analysis showed insufficient efficacy. Management reported strong sales for UZEDY, its long acting injectable for schizophrenia, and raised the product's revenue outlook. No safety concerns were identified for emrusolmin in the discontinued study, according to the company’s update. Teva’s halt of emrusolmin and upgraded UZEDY outlook only capture part of how its central...

      Nov 3Yahoo FinanceTEVA
      Why Is Teva Pharmaceutical Stock Gaining Tuesday? - Teva Pharmaceutical Indus (NYSE:TEVA)
      Nov 3BenzingaTEVA
      Teva (TEVA) Stock Still Looks Like A Bargain On Cash Flow
      Nov 3Yahoo FinanceTEVA
      Teva Q3 2026 slides: biopharma shift lifts margins to 58.7%
      Nov 3Investing.comTEVA
      Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
      Nov 3ReutersTEVA
      Teva Pharmaceutical Indus Q3 2026 Earnings Call Transcript
      Nov 3BenzingaTEVA
      Teva buys U.S. rights for Samsung Bioepis biosimilars (TEVA)

      Teva Pharmaceutical (TEVA) stock is in focus as the company gains U.S. rights to two biosimilars owned by Samsung Bioepis. Read more here.

      Nov 3Seeking AlphaTEVA
      UniQure gets an FDA decision date; Teva scraps brain drug study
      Nov 3Yahoo FinanceQURETEVA
      Top 6% Pharma Raises Outlook On Third-Quarter Beat

      Teva stock advanced early Tuesday on better-than-expected third-quarter metrics and a raised outlook for 2026.

      Nov 3Investor's Business DailyTEVA
      Teva stock gains after raising 2026 outlook (TEVA:NYSE)
      Nov 3Seeking AlphaTEVA
      Teva ADR earnings beat by $0.14, revenue topped estimates
      Nov 3Investing.comTEVA
      Teva Pharmaceutical Q3 profit gain beats estimates
      Nov 3ReutersTEVA
      Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
      Nov 3Yahoo FinanceTEVA
      Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
      Nov 3Yahoo FinanceTEVA
      Why is Teva Pharma ADR stock sliding today?
      Nov 2Investing.comTEVA
      Why Is Teva Stock Trading Lower on Monday?
      Nov 2BenzingaTEVA
      Teva shares slide after drug trial discontinuation
      Nov 2Yahoo FinanceTEVA
      Teva Pharmaceuticals to Halt Phase 2 Trial of Neurodegenerative Drug Emrusolmin Over Lack of Efficacy
      Nov 2Yahoo FinanceTEVA
      Teva to discontinue mid-stage neurodegenerative disorder study
      Nov 2ReutersTEVA
      Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
      Nov 2Yahoo FinanceTEVA
      H.C. Wainwright initiates Teva Pharma stock coverage with buy rating
      Nov 2Investing.comTEVA
      Teva: I Still See Upside After A Massive Rally (NYSE:TEVA)

      Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals. Read more on TEVA here.

      Oct 31Seeking AlphaTEVA

      This is the newest page. Registered accounts read further back.